The M1C ADC was active against MUC1-positive, but not MUC1-negative, breast and lung cancer cells (37); however, it is not known if this agent has activity against CRPC/NEPC cells, particularly in the setting of drug resistance. Here, MUC1 is linked to lung carcinoma.